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OBJECTIVE — We evaluated whether participation in a community-based group diabetes
prevention program might lead to relative changes in composite 10-year coronary heart disease
(CHD) risk for overweight adults with abnormal glucose metabolism.
RESEARCH DESIGN AND METHODS — We used the UK Prospective Diabetes Study
engine to estimate CHD risk for group-lifestyle and brief counseling (control) groups. Between-
group risk changes after 4 and 12 months were compared using ANCOVA.
RESULTS — Baseline 10-year risk was similar between treatment groups (P  0.667). At 4
and 12 months, the intervention group experienced signiﬁcant decreases in 10-year risk from
baseline (3.28%, P  0.001; and 2.23%, P  0.037) compared with control subjects
(0.78%, P  0.339; and 1.88%, P  0.073). Between-group differences were statistically
signiﬁcant and increased from the 4- to 12-month visits.
CONCLUSIONS — Community-baseddeliveryoftheDiabetesPreventionProgramlifestyle
intervention could be a promising strategy to prevent both CHD and type 2 diabetes in adults
with pre-diabetes.
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A
dults with pre-diabetes have in-
creased cardiometabolic risk, and
intensive lifestyle interventions
have been shown to improve their risk
factor control (1–3). In this article, we
evaluate the hypothesis that the Diabe-
tes Education & Prevention with a Life-
style Intervention Offered at the YMCA
(DEPLOY) pilot study reduces the com-
posite 10-year coronary heart disease
(CHD) risk in overweight adults with ab-
normal glucose metabolism.
RESEARCH DESIGN AND
METHODS— The DEPLOY study’s
design,participantcharacteristics,andre-
sults have been published separately (4).
Brieﬂy, of 131 individuals who met
screening criteria at two Greater India-
napolis YMCA facilities, 92 interested
adults enrolled. All participants had an
elevated BMI (24 kg/m
2), an American
Diabetes Association risk questionnaire
scoreof10orhigher(5),andanabnormal
whole-blood glucose concentration de-
termined by a ﬁnger stick (110–199
mg/dl or 100–199 mg/dl if fasting 9 h).
Exclusioncriteriaincludedanexistingdi-
agnosis of diabetes or any comorbidity
that could limit lifespan to 3 years or
contraindicate light-moderate physical
activity. Before implementation, one of
the two matched YMCA sites was ran-
domly assigned to receive training and
support for delivering a formal, group-
based adaptation of the Diabetes Preven-
tion Program (DPP) lifestyle intervention.
The control site only provided infor-
mation about existing YMCA wellness
programs.
Indiana University School of Medi-
cineresearchstaffmeasuredbodyweight,
systolic blood pressure (SBP), A1C, total
cholesterol, and HDL cholesterol at base-
line and at 4–6 and 12–14 months after
enrollment.AOne-TouchUltrahandheld
glucose meter was used to determine the
whole-blood glucose concentration (6),
and A1C was assessed from a ﬁnger-stick
capillary blood sample using a DCA 2000
analyzer (7,8). Total and HDL cholesterol
were measured from capillary blood us-
ing an LDX lipid analyzer (9,10). While
seated and relaxed for at least 5 min, par-
ticipants’ SBP was assessed once at each
visit with an aneroid sphygmomanome-
ter. The Indiana University/Purdue Uni-
versity Indianapolis Institutional Review
Board approved the study.
Ten-year risk of CHD was predicted
using the UK Prospective Diabetes Study
(UKPDS) risk engine and setting diabetes
duration to zero. The model is based on
CHD events from UKPDS participants
with type 2 diabetes; it incorporates A1C,
ageatdiagnosis,timesincediagnosis,sex,
smoking, SBP, total cholesterol–to–HDL
cholesterol ratio, and race (11). Although
the UKPDS engine has not yet been vali-
dated for risk prediction in pre-diabetes,
itistheonlynonproprietaryengineweare
aware of that incorporates blood pres-
sure, cholesterol, and A1C. Moreover,
A1Chasbeenshowntopredictcardiovas-
cular disease risk even at the lowest range
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(11,12). We chose this approach to max-
imizesensitivityforestimatingtherelative
impact of a lifestyle intervention on
changesinallthreeriskfactorscombined,
not to provide absolute risk estimates.
Intervention and control group base-
line CHD risk scores were compared us-
ing Student’s t test. Change in CHD risk
was calculated as 4- or 12-month risk mi-
nus baseline risk. Between-group risk
changes were compared using ANCOVA
with the baseline CHD risk as a covariate.
Analyses were performed using SAS ver-
sion 9.1 (SAS Institute, Cary, NC).
RESULTS— The mean baseline 10-
year risks for intervention and control
groupsweresimilar(11.9%[95%CI9.3–
14.6] and 11.1% [8.2–14.0], respec-
tively; P  0.667). At 4 and 12 months
(Table 1), the intervention group experi-
encedsigniﬁcantdecreasesin10-yearrisk
from baseline; between 4 and 12 months,
the CHD risk increased, but not back to
baseline levels. After 4 months, the control
groupexperiencedaninsigniﬁcantdecrease
in predicted 10-year CHD risk; at 12
months, mean CHD risk increased 2%
over baseline (P  0.073). Compared with
the control group, the intervention group
experiencedgreaterreductionsinpredicted
CHD risk at each follow-up visit. Between-
group differences increased from the 4- to
12-month follow-up visits.
Secondary analyses of individual risk
factor changes showed either no change
or minimal improvement in A1C and SBP
at4and12monthsforbothgroups.How-
ever, the total cholesterol–to–HDL cho-
lesterolratiodecreasedsigniﬁcantlyinthe
intervention group, whereas control sub-
jects showed either no change or signiﬁ-
cant increase, suggesting that changes in
the total cholesterol–to–HDL cholesterol
ratio explained much of the between-
group difference in predicted CHD risk.
CONCLUSIONS — In the DEPLOY
study, a DPP lifestyle intervention deliv-
ered in YMCA facilities by centrally
trained lay group instructors had a statis-
tically signiﬁcant and clinically meaning-
ful impact on composite cardiometabolic
risk as estimated by the UKPDS risk en-
gine. This is consistent with effects of the
original DPP lifestyle intervention, i.e.,
improved blood pressure, triglycerides,
LDL cholesterol, fasting plasma glucose,
and HDL cholesterol levels (13).
Although the UKPDS risk engine is
speciﬁc to people with type 2 diabetes,
baseline CHD risk estimates for our
study population were similar to those
of newly diagnosed participants in the
UKPDS study (11). Compared with the
UKPDS sample, DEPLOY participants
were on average 6 years older and
more often female (56 vs. 42%), with
lower A1C (5.6 vs. 6.7 mg/dl), compa-
rable SBP, lower total cholesterol (188
vs. 209 mg/dl), and higher HDL choles-
terol (46 vs. 43 mg/dl).
This was a small study with notable
limitations. First, we used the diabetes-
speciﬁc UKPDS risk engine to predict rel-
ative probabilities for CHD in persons
with pre-diabetes. Because we set dura-
tion of diabetes to zero and it may take
several years for diabetes to develop, the
predicted risk may be overestimated.
However, intervention and control
groups were enrolled using identical cri-
teria; thus, any possible overestimate of
riskshouldoccursimilarlyinbothgroups
and should not affect comparisons. Sec-
ond, at 12 months there was an approxi-
mate 33% overall dropout rate; however,
it was similar between groups. Further-
more, baseline 10-year CHD risk and all
risk factors included in the CHD risk cal-
culation were similar for dropouts and
nondropouts in each group. Third, the
control group experienced a greater and
more rapid increase in CHD risk between
4 and 12 months mediated largely by in-
creases in the total cholesterol–to–HDL
cholesterolratiocomparedwiththeinter-
vention group, contributing signiﬁcantly
to the between-group difference.
In conclusion, signiﬁcant reductions
in estimated 10-year CHD risk suggest
that this model for community-based de-
livery of the DPP lifestyle intervention
could have a signiﬁcant effect on preven-
tion of both CHD and type 2 diabetes in
overweight adults with abnormal glucose
metabolism.
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